BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $26

Futu NewsJan 13 20:31 · Ratings

Klinge Biopharma Signs License Deal for Formycon's Eylea Biosimilar

MT NewswiresJan 13 15:20

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea (Aflibercept) in Major Parts of Europe and in Israel

GlobeNewswireJan 13 14:00

FDA Says Teva Pharmaceuticals USA's Ethinyl Estradiol; Norethindrone Tablet, Chewable Has Been Discontinued

BenzingaJan 11 00:56

Samsung Bioepis and Teva Enter Into a Strategic Partnership for Commercialization of EPYSQLI (Eculizumab-aagh) in the United States

GlobeNewswireJan 10 21:30

Pharma Companies Welcome New Year With 583 Drug Price Hikes so Far

Seeking AlphaJan 10 04:36